Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)

PURPOSE: To compare the efficacy of ranibizumab 0.5-mg and 2.0-mg intravitreal injections for persistent diabetic macular edema (DME) previously treated with bevacizumab. METHODS: In all, 43 patients with residual center-involved DME following intravitreal bevacizumab were included in this 12-month...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eye (Lond)
Main Authors: Dhoot, D S, Pieramici, D J, Nasir, M, Castellarin, A A, Couvillion, S, See, R F, Steinle, N, Bennett, M, Rabena, M, Avery, R L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4816366/
https://ncbi.nlm.nih.gov/pubmed/25633882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/eye.2014.338
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados